Exploring Immunotherapy in Colorectal Cancer

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2022 Jul 16

PMID 35842707

Authors

Junyong Weng

Shanbao Li

Zhonglin Zhu

Qi Liu

Ruoxin Zhang

Yufei Yang

Xinxiang Li

Affiliations

Soon will be listed here.

Abstract

Chemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characteristics of the tumor cells, it is difficult to make breakthroughs in traditional strategies. The immune checkpoint blockades (ICB) therapy has made significant progress in the treatment of advanced malignant tumors, and patients who benefit from this therapy may obtain a long-lasting response. Unfortunately, immunotherapy is only effective in a limited number of patients with microsatellite instability-high (MSI-H), and segment initial responders can subsequently develop acquired resistance. From September 4, 2014, the first anti-PD-1/PD-L1 drug Pembrolizumab was approved by the FDA for the second-line treatment of advanced malignant melanoma. Subsequently, it was approved for mCRC second-line treatment in 2017. Immunotherapy has rapidly developed in the past 7 years. The in-depth research of the ICB treatment indicated that the mechanism of colorectal cancer immune-resistance has become gradually clear, and new predictive biomarkers are constantly emerging. Clinical trials examining the effect of immune checkpoints are actively carried out, in order to produce long-lasting effects for mCRC patients. This review summarizes the treatment strategies for mCRC patients, discusses the mechanism and application of ICB in mCRC treatment, outlines the potential markers of the ICB efficacy, lists the key results of the clinical trials, and collects the recent basic research results, in order to provide a theoretical basis and practical direction for immunotherapy strategies.

Citing Articles

Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy.

Jiao J, Wu Y, Wu S, Jiang J Curr Treat Options Oncol. 2025; .

PMID: 40045029 DOI: 10.1007/s11864-025-01306-8.

Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade.

Li Z, Liu S, Liu D, Yang K, Xiong J, Fang Z J Exp Clin Cancer Res. 2025; 44(1):84.

PMID: 40038799 PMC: 11881293. DOI: 10.1186/s13046-025-03318-6.

Frontiers and Controversies in De Novo Gastrointestinal Tumors After Organ Transplantation: Current Progress and Future Directions.

Xu X, Zhang S, Luo Z, Zheng Y, Kong T, Huang C Ann Surg Oncol. 2025; .

PMID: 40035907 DOI: 10.1245/s10434-025-16975-w.

LBP-CD155 Liposome Nanovaccine Efficiently Resist Colorectal Cancer and Enhance ICB Therapy.

Yan Y, Duan T, Xue X, Yang X, Liu M, Ma B Int J Nanomedicine. 2025; 20:1047-1063.

PMID: 39877587 PMC: 11773180. DOI: 10.2147/IJN.S492734.

Prognostic models of immune-related cell death and stress unveil mechanisms driving macrophage phenotypic evolution in colorectal cancer.

Liu H, Zhang C, Peng S, Yin Y, Xu Y, Wu S J Transl Med. 2025; 23(1):127.

PMID: 39875913 PMC: 11776142. DOI: 10.1186/s12967-025-06143-9.

References

Venderbosch S, Nagtegaal I, Maughan T, Smith C, Cheadle J, Fisher D . Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20):5322-30. PMC: 4201568. DOI: 10.1158/1078-0432.CCR-14-0332. View

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

Taylor N, Vick S, Iglesia M, Brickey W, Midkiff B, McKinnon K . Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J Clin Invest. 2017; 127(9):3472-3483. PMC: 5669567. DOI: 10.1172/JCI90499. View

Dong X, Lv S, Zhang X, Hao R . Upregulation of LAGE3 correlates with prognosis and immune infiltrates in colorectal cancer: A bioinformatic analysis. Int Immunopharmacol. 2020; 85:106599. DOI: 10.1016/j.intimp.2020.106599. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Boland C, Thibodeau S, Hamilton S, Sidransky D, Eshleman J, Burt R . A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58(22):5248-57. View

Baruch E, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L . Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2020; 371(6529):602-609. DOI: 10.1126/science.abb5920. View

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

10.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

11.

Blaeschke F, Paul M, Schuhmann M, Rabsteyn A, Schroeder C, Casadei N . Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. Cytotherapy. 2019; 21(9):973-986. DOI: 10.1016/j.jcyt.2019.06.009. View

12.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

13.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

14.

Cona M, Lecchi M, Cresta S, Damian S, Del Vecchio M, Necchi A . Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. Cancers (Basel). 2019; 11(2). PMC: 6406250. DOI: 10.3390/cancers11020223. View

15.

Duchartre Y, Kim Y, Kahn M . The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016; 99:141-9. PMC: 5853106. DOI: 10.1016/j.critrevonc.2015.12.005. View

16.

Foon K, Chakraborty M, John W, Sherratt A, Kohler H . Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest. 1995; 96(1):334-42. PMC: 185205. DOI: 10.1172/JCI118039. View

17.

Schrock A, Ouyang C, Sandhu J, Sokol E, Jin D, Ross J . Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019; 30(7):1096-1103. DOI: 10.1093/annonc/mdz134. View

18.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

19.

Koopman M, Kortman G, Mekenkamp L, Ligtenberg M, Hoogerbrugge N, Antonini N . Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009; 100(2):266-73. PMC: 2634718. DOI: 10.1038/sj.bjc.6604867. View

20.

Koyama S, Akbay E, Li Y, Aref A, Skoulidis F, Herter-Sprie G . STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016; 76(5):999-1008. PMC: 4775354. DOI: 10.1158/0008-5472.CAN-15-1439. View